SOLNA, STOCKHOLM REGION, SWEDEN – December 15, 2025 – Barnik Invest announces an initial investment in MedStorm Innovation AS. MedStorm Innovation is a medical technology company specializing in the objective, real-time assessment of pain and nociception across all age groups.
MedStorm’s core technology measures skin sympathetic nerve activity via skin conductance, reflecting changes in emotional sweating triggered by acetylcholine on muscarinic receptors. This provides clinicians with an accurate, numeric output to guide pain management and treatment.
Founded by Professor Hanne Storm, MD, PhD, at the University of Oslo, MedStorm began research in neonatal pain assessment in 1999. The company’s CE-certified PainMonitor, launched in 2009, is widely adopted and validated by over 80 independent studies for guiding analgesic dosing in NICUs, PICUs, and surgical settings.
For more information, please contact;
Hamid Bakhshi, CEO
Telephone: +46738531165
E-mail: info@barnikinvest.com
About Barnik Invest Group
Barnik Invest Group is a leading 360 solution partner for Life Science companies in the Nordics. The company provides a comprehensive suite of services to support its portfolio companies, including capital, clinical development, expertise, and commercialization. Through its fully owned subsidiaries, Medicorent and StartUpPharma, Barnik Invest offers CRO services, outsourcing, recruitment, distribution, product development, and commercialization solutions. Barnik’s mission is to nurture promising life science companies from early clinical development to commercialization, enabling them to achieve positive cash flows or successful exits, and ultimately enhancing patient well-being and improving human health worldwide. For more information, visit www.barnikinvest.com.
